Report Ocean introduces a fresh report examining the ‘Global Conjugate Vaccines Market’, encompassing its size, share, growth, industry trends, and forecast up to 2032. This comprehensive analysis delves into various industry components and growth patterns that offer valuable insights for anticipating the market’s future trajectory.
The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.
Request to Download Free Sample Copy of ‘Global Conjugate Vaccines Market’ Report: -https://reportocean.us/sample-request/report_id/IND95
Disease indication segment insights:
Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017-2022.
End user segment insights:
The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.
Regional insights:
Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the regions widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.
Companies covered:
1. GlaxoSmithKline
2. Pfizer Inc.
3. Merck & Co.
4. Novartis
5. Sanofi Pasteur
6. CSL Limited
7. Bharat Biotech International
8. Biological E Limited
9. Serum Institute of India
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada)
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa)
Some Questions Answered in the Conjugate Vaccines Market Report:
- What is the projected size of the global Conjugate Vaccines market in 2032, and what growth rate is expected?
- What are the primary drivers of growth in the global Conjugate Vaccines industry?
- What are the major market trends that are affecting the expansion of the Conjugate Vaccines market?
- What obstacles must be overcome in order to achieve sustained growth in the Conjugate Vaccines market?
- What opportunities and threats do vendors in the global Conjugate Vaccines market face?
- What are the raw materials and manufacturing equipment used in the production of Conjugate Vaccines, and what is the manufacturing process?
- What are the different types and applications of Conjugate Vaccines, and what is the market share of each type and application?
- What factors, such as trends, challenges, and risk factors, are currently shaping the growth of the Conjugate Vaccines market?
- What factors are driving the growth of the Conjugate Vaccines market in the top regions worldwide?
- Who are the major players in the global Conjugate Vaccines market, and what strategies are they employing to succeed?
- What industrial trends, drivers, and challenges are influencing the expansion of the Conjugate Vaccines market?
- What are the main findings of a five forces analysis of the global Conjugate Vaccines market?
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom-line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.